- We are growth equity and venture capital investors.
- Our average equity commitment is $10-30M over the duration of an investment.
- New Rhein has offices in the United States and Europe. We are geographically agnostic and open to investing globally.
We target companies that develop novel solutions to address large, underserved needs in healthcare.
Companies should have de-risked assets, with at least initial safety and efficacy data in humans. 505b2 products are of high interest, as well as products with strong clinical proof of concept data.
We believe that "Innovation drives greater risk-adjusted return than Invention". Treatments today must improve access and reduce costs. One way to do so is to innovate upon existing science and existing products, rather than inventing new approaches.
Companies should have a clearly defined path to approval, validated by regulatory bodies, and supported by a feasible and practical execution plan.
Products should be clearly differentiated in one or more of the following ways: safer, more effective, more compliantly used by patients, and lower cost. Orphan designations are of high interest.
